Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering Sees Growth Opportunity For Organon Products In The U.S. – Hassan

Executive Summary

Schering-Plough sees significant growth potential for Organon's products that currently are marketed in the U.S., CEO Fred Hassan said March 20

You may also be interested in...



FTC investigating Schering/Organon merger

The Federal Trade Commission is requesting additional information from Schering-Plough regarding its planned acquisition of Akzo Nobel's pharmaceutical and animal health business, Organon Biosciences. Despite FTC's request, Schering continues to expect the $14.4 billion transaction to be completed by the end of 2007 (1"The Pink Sheet" March 26, 2007, p. 25)...

FTC investigating Schering/Organon merger

The Federal Trade Commission is requesting additional information from Schering-Plough regarding its planned acquisition of Akzo Nobel's pharmaceutical and animal health business, Organon Biosciences. Despite FTC's request, Schering continues to expect the $14.4 billion transaction to be completed by the end of 2007 (1"The Pink Sheet" March 26, 2007, p. 25)...

Schering Jumps On Organon Buy; Will Late-Stage M&A Keep Fueling Pharma?

Pharmaceutical companies unveiling mergers and acquisitions in the first quarter were among those rewarded by Wall Street

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048183

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel